Effects of GRK5 and ADRB1 polymorphisms influence on systolic heart failure

Journal of Translational Medicine

Volumn 13, Issue 1, 2015, Pages

  Kang, Sheng ^a   Hong, Xuan ^a   Ruan, Chang wu ^b   Yu, Ping ^a   Yu, Shan shan ^a   Chen, Ming ^a   Zhang, Dai fu ^c   Fan, Hui min ^a   Liu, Zhong min ^a  

^a Key Laboratory of Arrhythmias of Ministry of Education   (China)

^b Shanghai 8th People's Hospital   (China)

^c Pudong New Area People's Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; G PROTEIN COUPLED RECEPTOR KINASE 5; GLUTAMINE; GLYCINE; LEUCINE; ADRB1 PROTEIN, HUMAN; GRK5 PROTEIN, HUMAN;

ADRB1 GENE; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHINESE; CROSS-SECTIONAL STUDY; DRUG USE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GRK5 GENE; HUMAN; INTERVIEW; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MORBIDITY; QUESTIONNAIRE; RISK ASSESSMENT; SYSTOLIC HEART FAILURE; TREATMENT RESPONSE; BIOLOGICAL MODEL; DNA SEQUENCE; GENETICS; HEART FAILURE, SYSTOLIC; MOLECULAR GENETICS; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADRENERGIC BETA-ANTAGONISTS; BASE SEQUENCE; G-PROTEIN-COUPLED RECEPTOR KINASE 5; HEART FAILURE, SYSTOLIC; HUMANS; MODELS, GENETIC; MOLECULAR SEQUENCE DATA; MULTIVARIATE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ADRENERGIC, BETA-1; SEQUENCE ANALYSIS, DNA;

EID: 84924289854     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-015-0402-7     Document Type: Article

References (32)

1. Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004;292(3):344-50.
2. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, et al. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113(6):e85-151.
3. Kim J, Ahn S, Ren XR, Whalen EJ, Reiter E, Wei H, et al. Functional antagonism of different G protein-coupled receptor kinases for beta-arrestin-mediated angiotensin II receptor signaling. Proc Natl Acad Sci U S A. 2005;102(5):1442-7.
4. Franz WM, Müller OJ, Katus HA. Cardiomyopathies: from genetics to the prospect of treatment. Lancet. 2001;358(9293):1627-37.
5. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344(22):1659-67.
6. Wagoner LE, Craft LL, Singh B, Suresh DP, Zengel PW, McGuire N, et al. Polymorphisms of the beta(2)-adrenergic receptor determine exercise capacity in patients with heart failure. Circ Res. 2000;86(8):834-40.
7. Kohout TA, Lefkowitz RJ. Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization. Mol Pharmacol. 2003;63(1):9-18.
8. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2001;38(7):2101-13.
9. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, Weber SA, Greene SM, Hodne D, et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A. 2006;103(30):11288-93.
10. Liggett SB, Cresci S, Kelly RJ, Syed FM, Matkovich SJ, Hahn HS, et al. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med. 2008;14(5):510-7.
11. Mialet Perez J, Rathz DA, Petrashevskaya NN, Hahn HS, Wagoner LE, Schwartz A, et al. Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med. 2003;9(10):1300-5.
12. Sehnert AJ, Daniels SE, Elashoff M, Wingrove JA, Burrow CR, Horne B, et al. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. J Am Coll Cardiol. 2008;52(8):644-51.
13. Kurnik D, Li C, Sofowora GG, Friedman EA, Muszkat M, Xie HG, et al. Beta-1-adrenoceptor genetic variants and ethnicity independently affect response to beta-blockade. Pharmacogenet Genomics. 2008;18(10):895-902.
14. Kang S, Fan HM, Li J, Fan LY, Miao AY, Bao Y, et al. Relationship of arterial stiffness and early mild diastolic heart failure in general middle and aged population. Eur Heart J. 2010;31(22):2799-807.
15. Kang S, Fan HM, Li J, Fan LY, Chen M, Liu ZM. Heart Failure Risk Factors Investigation Project collaborative group (HFRFIP collaborative group): Relationship of aortic stiffness, central systolic blood pressure and left atrium enlargement in general middle and aged population. Int J Cardiol. 2012;154(3):344-7.
16. Lee DS, Pencina MJ, Benjamin EJ, Wang TJ, Levy D, O'Donnell CJ, et al. Association of parental heart failure with risk of heart failure in offspring. N Engl J Med. 2006;355(2):138-47.
17. Podlowski S, Wenzel K, Luther HP, Müller J, Bramlage P, Baumann G, et al. Beta1-adrenoceptor gene variations: a role in idiopathic dilated cardiomyopathy? J Mol Med (Berl). 2000;78(2):87-93.
18. Johnson M. The beta-adrenoceptor. Am J Respir Crit Care Med. 1998;158(5 Pt 3):S146-53.
19. Cresci S, Kelly RJ, Cappola TP, Diwan A, Dries D, Kardia SL, et al. Clinical and genetic modifiers of long-term survival in heart failure. J Am Coll Cardiol. 2009;54(5):432-44.
20. Kurnik D, Cunningham AJ, Sofowora GG, Kohli U, Li C, Friedman EA, et al. GRK5 Gln41Leu polymorphism is not associated with sensitivity to beta(1)-adrenergic blockade in humans. Pharmacogenomics. 2009;10(10):1581-7.
21. White HL, de Boer RA, Maqbool A, Greenwood D, van Veldhuisen DJ, Cuthbert R, et al. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur J Heart Fail. 2003;5(4):463-8.
22. Liggett SB, Tepe NM, Lorenz JN, Canning AM, Jantz TD, Mitarai S, et al. Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation. 2000;101(14):1707-14.
23. Asai K, Yang GP, Geng YJ, Takagi G, Bishop S, Ishikawa Y, et al. Beta-adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic G(salpha) mouse. J Clin Invest. 1999;104(5):551-8.
24. Okumura S, Takagi G, Kawabe J, Yang G, Lee MC, Hong C, et al. Disruption of type 5 adenylyl cyclase gene preserves cardiac function against pressure overload. Proc Natl Acad Sci U S A. 2003;100(17):9986-90.
25. Matkovich SJ, Diwan A, Klanke JL, Hammer DJ, Marreez Y, Odley AM, et al. Cardiac-specific ablation of G-protein receptor kinase 2 redefines its roles in heart development and beta-adrenergic signaling. Circ Res. 2006;99(9):996-1003.
26. Jin B, Ge-Shang QZ, Li Y, Shen W, Shi HM, Ni HC. A meta-analysis of β1-adrenergic receptor gene polymorphisms in idiopathic dilated cardiomyopathy. Mol Biol Rep. 2012;399(1):563-7.
27. O'Connor CM, Fiuzat M, Carson PE, Anand IS, Plehn JF, Gottlieb SS, et al. Combinatorial pharmacogenetic interactions of bucindolol and β1, α2C adrenergic receptor polymorphisms. PLoS One. 2012;7(10):e44324.
28. Bristow MR, Krause-Steinrauf H, Nuzzo R, Liang CS, Lindenfeld J, Lowes BD, et al. Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial. Circulation. 2004;110(11):1437-42.
29. Molenaar P, Chen L, Semmler AB, Parsonage WA, Kaumann AJ. Human heart beta-adrenoceptors: beta1-adrenoceptor diversification through 'affinity states' and polymorphism. Clin Exp Pharmacol Physiol. 2007;34(10):1020-8.
30. Terra SG, Hamilton KK, Pauly DF, Lee CR, Patterson JH, Adams KF, et al. Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenet Genomics. 2005;15(4):227-34.
31. Kao DP, Davis G, Aleong R, O'Connor CM, Fiuzat M, Carson PE, et al. Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. Eur J Heart Fail. 2013;15(3):324-33.
32. Liu J, Liu ZQ, Tan ZR, Chen XP, Wang LS, Zhou G, et al. Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin Pharmacol Ther. 2003;74(4):372-9.